Discovery of novel coumarin triazolyl and phenoxyphenyl triazolyl derivatives targeting amyloid beta aggregation-mediated oxidative stress and neuroinflammation for enhanced neuroprotection.

CE5, a promising lead compound for Alzheimer's therapy, targets anti-amyloid beta aggregation, oxidative stress reduction, and inflammation modulation mechanisms.